{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:22Z","timestamp":1788265102877,"version":"build-2803163510"},"reference-count":21,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Fludarabine, cyclophosphamide and rituximab (FCR) is a first-line therapy for fit treatment-naive patients with chronic lymphocytic leukemia (CLL); however, its hematotoxicity and related infections necessitate more efficacious, safer treatments. Zanubrutinib is a highly potent and selective next-generation Bruton tyrosine kinase inhibitor approved for treatment-naive patients with CLL and small lymphocytic lymphoma. Given the absence of clinical trials providing head-to-head comparisons, the aim of this analysis was to conduct a matching-adjusted indirect comparison between zanubrutinib and FCR.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Patient-level data from SEQUOIA (zanubrutinib vs bendamustine\u00a0+\u00a0rituximab [BR]) was adjusted for interpopulation differences through propensity-score matching with aggregate data from the CLL10 trial (FCR vs BR). Progression-free survival (PFS) was compared among populations matched for immunoglobulin heavy-chain gene mutation, 11q deletion, \u03b22-microglobulin, Binet stage and age. Sensitivity analyses incorporated geographic region, sex, creatinine clearance, the Cumulative Illness Rating Scale, Eastern Cooperative Oncology Group performance status and previous infections.\n                    <jats:bold>Results:<\/jats:bold>\n                    Zanubrutinib improved PFS compared with FCR, with a hazard ratio of 0.41 (95% CI: 0.20\u20130.81; effective sample size 174). Including geographic region, Eastern Cooperative Oncology Group performance status or previous infections as matching factors one by one in the propensity score model showed similar results. Incorporating Cumulative Illness Rating Scale or creatinine clearance showed numerically favorable PFS with zanubrutinib (hazard ratio [95% CI] 0.45 [0.16\u20131.24] and 0.52 [0.24\u20131.13], respectively), owing to the low effective sample size of the expanded model (64 and 123, respectively).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our findings suggest that zanubrutinib offers improved PFS over FCR in fit, treatment-naive patients with CLL, further supporting zanubrutinib as a first-line CLL treatment for multiple patient profiles.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0192","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:50:12Z","timestamp":1787309412000},"source":"Crossref","is-referenced-by-count":0,"title":["Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-na\u00efve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"first","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Barnieh","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd, Netherlands BV, Schiphol, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Jevdjevic","sequence":"additional","affiliation":[{"name":"Precision AQ, HEOR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bouwmeester","sequence":"additional","affiliation":[{"name":"Precision AQ, HEOR, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd, San Carlos, CA 94070, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"12","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek M","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines. Blood 111(12), 5446\u20135456 (2008).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst B","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32(1), 23\u201333 (2021).","journal-title":"Ann. Oncol."},{"key":"#cr-split#-e_1_3_10_5_2.1","unstructured":"Surveillance Research Program NCI. SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program National Cancer Institute. Data source(s): U.S. Mortality Data (1969-2022) National Center for Health Statistics CDC. (2024 Apr 17 [updated: 2024 Nov 5"},{"key":"#cr-split#-e_1_3_10_5_2.2","unstructured":"cited 2025 Jan 21]). https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"issue":"9747","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek M","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747), 1164\u20131174 (2010).","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede V","year":"2014","unstructured":"Goede V, Fischer K, Busch R Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370(12), 1101\u20131110 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst B","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann. Oncol. 35(9), 762\u2013768 (2024).","journal-title":"Ann. Oncol."},{"issue":"7","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst B","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17(7), 928\u2013942 (2016).","journal-title":"Lancet Oncol."},{"issue":"2","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer K","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2), 208\u2013215 (2016).","journal-title":"Blood"},{"issue":"8","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam CS","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 23(8), 1031\u20131043 (2022).","journal-title":"Lancet Oncol."},{"issue":"2","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"4","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman JP","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia 36(4), 1171\u20131175 (2022).","journal-title":"Leukemia"},{"issue":"9","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf O","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 21(9), 1188\u20131200 (2020).","journal-title":"Lancet Oncol."},{"issue":"26","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl. J. Med. 379(26), 2517\u20132528 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373(25), 2425\u20132437 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi F","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J. Am. Geriatr. Soc. 56(10), 1926\u20131931 (2008).","journal-title":"J. Am. Geriatr. Soc."},{"key":"e_1_3_10_18_2","article-title":"NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE","author":"Phillippo DM","year":"2016","unstructured":"Phillippo DM, Ades AE, Dias S NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE. DSU (2016). https:\/\/research-information.bris.ac.uk\/files\/94868463\/Population_adjustment_TSD_FINAL.pdf","journal-title":"DSU"},{"key":"e_1_3_10_19_2","unstructured":"The Comprehensive R Archive Network. R CRAN version 4.0.2. https:\/\/cran.r-project.org\/bin\/windows\/base\/old\/"},{"key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1097\/01.HS9.0000850404.50582.cb","article-title":"PB1888: efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis","volume":"6","author":"Chanan-Khan A","year":"2022","unstructured":"Chanan-Khan A, Yang K, Liu T PB1888: efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis. HemaSphere 6, 1767\u20131768 (2022).","journal-title":"HemaSphere"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2025.101088"},{"key":"e_1_3_10_22_2","article-title":"Clinical Study Report (CSR): international, phase 3, open-label, randomized study of BGB-3111 compared with bendamustine plus rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","author":"BeiGene","year":"2022","unstructured":"BeiGene. Clinical Study Report (CSR): international, phase 3, open-label, randomized study of BGB-3111 compared with bendamustine plus rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. BeiGene (2022).","journal-title":"BeiGene"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:45:44Z","timestamp":1788263144000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.57264\/cer-2025-0192"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0192","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"e250192"}}